Company Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors.
In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
| Country | Ontario, Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
Contact Details
Address: 2 Bloor St W., 7th Floor Toronto, A6 M4W 3E2 Ontario, Canada | |
| Phone | 416 648-5555 |
Stock Details
| Ticker Symbol | MDNAF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001807983 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fahar Merchant | Founder, Chairman, Chief Executive Officer and Pres |
| Rosemina Merchant | Founder, Chief Development Officer and Director |
| Elizabeth Williams C.A., CPA, CPA, CA | Chief Financial Officer and Corporate Secretary |
| Dr. John H. Sampson M.D., Ph.D., MBA | Chief Clinical Advisor |
| Dr. Martin Bexon M.D. | Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 15-12G | Securities registration termination |
| May 14, 2024 | D | Notice of Exempt Offering of Securities |
| May 13, 2024 | EFFECT | Notice of Effectiveness |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 10, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 26, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 22, 2024 | AW | Amendment Withdrawal Request |